2024 ASCO Direct Philadelphia

Learn How to Claim Your Credit

Total Health's 2024 ASCO Direct™ Philadelphia Conference is an officially licensed ASCO Direct meeting. This Post ASCO Review showcases abstracts from highly rated presentations, allowing attendees to engage with the latest research and strategies in oncology education. This accredited meeting will be hosted as a hybrid conference, featuring in-person attendance.

Accreditation Information | 7.25

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

• Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of 7.25 ANCC contact hours.

• Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 7.25 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• Learners Notification

  Learner Notification

  Objectives - After Attending This Program You Should Be Able To

  1. Integrate new evidence into everyday clinical practice, thereby improving the quality of care being delivered to patients living with and beyond cancer.

  2. Implement practice changes in a variety of treatment options for solid tumors, including lung, breast, melanoma, colorectal, non-colorectal GI, and GU cancers.

  3. Stimulate innovative strategies for new and additional research related to treatment and prevention.

  Disclosure of Conflict of Interest

  The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

  All individuals in a position to control the content of CE are listed below.

  Name Commercial Interest:Relationship

  Sramila Aithal Pfizer, , Daiichi, Astrazenaca, Gilead, Merck, Lily:Speakers Bureau

  Beth DuPree Perimeter Medical:Consultant Medtronic, Prelude Dx , Agendia:Speakers Bureau Caliber Medical, Gateway Sciences, Innerstill Health :Other

  Henry Fung N/A

  Shayma Kazmi Jazz:Speakers Bureau

  Richard Kim Incyte, Astra Zeneca, Abbvie, BMS, Bayer, Exelixis, Pfizer, Abbvie, Jazz, Roche:Consultant

  Catherine Lai Servier, Daiichi, Dava Oncology, Rigel, Genentech:Scientific/Medical Advisory Board Member BMS, AbbVie, Astellas:Consultant BMS, Jazz:Research Grant Site Principal Investigator

  ARTURO LOAIZA-BONILLA Guardant, Ipsen, Natera, AstraZeneca:Speakers Bureau Verily (Google/Alphabet), MedScape/WebMD, PSI CRO, Bayer, Astra-Zeneca, Cardinal Health, BrightInsight, The Lynx Group, Fresenius, Merck, Pfizer, Science37:Consultant BioLineRx:Public Stock Shareholder Massive Bio:Private Stock Shareholder

  Ravi Madan N/A

  Reshma Mahtani Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Gilead, Genentech, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, SeaGen, Sermonix, Stemline:Consultant Astra Zeneca, Genenetch, Veru:Research Grant Overall Principal Investigator

  Danny Markabawi N/A

  Marianne Sarcich N/A

  Rino Seedor Bristol Myers Squibb:Scientific/Medical Advisory Board Member

  Nagashree Seetharamu Genentech, Vaccinex, Amgen, Merck:Research Grant Overall Principal Investigator Astra Zeneca, Genentech, Takeda, Amgen, Pfizer, Mirati, BluePrint, Coherus:Scientific/Medical Advisory Board Member Boehringer Ingram:Consultant

  Jacob Svoboda Atara:Scientific/Medical Advisory Board Member Incyte, Kite, Merck, Adaptive:Research Grant Site Principal Investigator CRISPR Therapeutics, BMS/Celgene, Adaptive, Seagen, Pharmacyclics, Incyte, Astra-Zeneca:Consultant

  Victoria M. Villaflor Gilead, AstraZeneca, Novocure, Bristol Myers Squibb, Regeneron, Daiichi Sankyo, Genetech / Roche:Consultant TGen:Research Grant Overall Principal Investigator

  Reyna Wilhelm N/A

  Justin Kaiser N/A

How to Get Your Certificate

Go to thc.cmecertificateonline.com

Click on the ASCO Philadelphia 2024 link.

For ABIM MOC click on the ASCO Philadelphia 2024 ABIM MOC link.

Evaluate the meeting.

Print, download, or save your certificate for your records.

If you lose your certificate, or need help, go to help.cmecertificateonline.com